Department of Population and Data Sciences, UT Southwestern Medical Center, Dallas, Texas, United States.
Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas, United States.
J Viral Hepat. 2020 Jul;27(7):680-689. doi: 10.1111/jvh.13278. Epub 2020 Mar 2.
Achieving practice change can be challenging when guidelines shift from a selective risk-based strategy to a broader population health strategy, as occurred for hepatitis C (HCV) screening (2012-2013). We aimed to evaluate patient and provider barriers that contributed to suboptimal HCV screening and linkage-to-care rates after implementation of an intervention to improve HCV screening and linkage-to-care processes in a large, public integrated healthcare system following the guidelines change. As part of a mixed-methods study, we collected data through patient surveys (n = 159), focus groups (n = 9) and structured observation of providers and staff (n = 9). We used these findings to then inform domains for the second phase, which consisted of semi-structured interviews with patients across the screening-treatment continuum (n = 24) and providers and staff at primary care and hepatology clinics (n = 21). We transcribed and thematically analysed interviews using an integrated inductive and deductive framework. We identified lack of clarity about treatment cost, treatment complications and likelihood of cure as ongoing patient-level barriers to screening and linkage to care. Provider-level barriers included scepticism about establishing HCV screening as a quality metric given competing clinical priorities, particularly for patients with multiple comorbidities. However, most felt positively about adding HCV as a quality metric to enhance HCV screening and linkage to care. Provider engagement yielded suggestions for process improvements that resulted in increased stakeholder buy-in and real-time enhancements to the HCV screening process intervention. Systematic data collection at baseline and during practice change implementation may facilitate adoption and adaptation to improve HCV screening guideline implementation. Findings identified several key opportunities and lessons to enhance the impact of practice change interventions to improve HCV screening and treatment delivery.
当指南从基于选择性风险的策略转变为更广泛的人群健康策略时,实现实践变革可能具有挑战性,正如丙型肝炎 (HCV) 筛查 (2012-2013 年) 所发生的那样。我们旨在评估导致 HCV 筛查和治疗后衔接率不理想的患者和提供者障碍,在一项旨在改善大型公共综合医疗保健系统中 HCV 筛查和治疗后衔接过程的干预措施实施后,指南发生了变化。作为一项混合方法研究的一部分,我们通过患者调查 (n=159)、焦点小组 (n=9) 和对提供者和工作人员的结构化观察 (n=9) 收集数据。我们利用这些发现来确定第二阶段的研究领域,该阶段包括对跨越筛查-治疗连续体的患者 (n=24) 以及初级保健和肝脏病学诊所的患者和工作人员 (n=21) 进行半结构式访谈。我们使用综合归纳和演绎框架对访谈进行转录和主题分析。我们发现,治疗费用、治疗并发症和治愈可能性不明确是持续存在的患者筛查和治疗衔接障碍。提供者层面的障碍包括对将 HCV 筛查确立为质量指标的怀疑,因为存在竞争的临床优先事项,特别是对于患有多种合并症的患者。然而,大多数人对将 HCV 添加为质量指标以增强 HCV 筛查和治疗衔接持积极态度。提供者的参与提出了一些流程改进的建议,这导致了更多利益相关者的支持,并实时增强了 HCV 筛查流程干预措施。在实践变革实施过程中进行系统的数据收集可能有助于采用和适应,以改善 HCV 筛查指南的实施。研究结果确定了一些增强实践变革干预措施以改善 HCV 筛查和治疗提供的影响的关键机会和经验教训。